好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An Open-Label Pilot Trial Assessing the Safety and Efficacy of SPN-817 (Huperzine A Extended-Release) in Adults with Treatment-Resistant Focal Impaired Awareness Seizures
Epilepsy/Clinical Neurophysiology (EEG)
P12 - Poster Session 12 (5:30 PM-6:30 PM)
10-003
To assess the safety and efficacy of SPN-817 (Huperzine A extended-release) as an adjunctive therapy for the treatment of focal impaired awareness seizures (FIAS) in adults.
Despite a recent increase in available anti-seizure medications (ASM), approximately 30% of the patients do not achieve adequate seizure control. SPN-817 is a multifunctional compound that has been shown to reduce the frequency and severity of seizures in nonclinical studies. SPN-817 is known to be a potent acetylcholinesterase inhibitor with possible downstream activity on the GABAergic system. Nevertheless, its anticonvulsant mechanism of action remains to be fully elucidated. Here we report the clinical outcome of three adult subjects with chronic drug-resistant epilepsy receiving long-term adjunctive SPN-817 treatment.

This is an ongoing, open-label, add-on pilot study in adult subjects with frequent FIAS receiving stable doses (for at least 4 weeks) of 1–4 currently available ASM. The study consisted of a 96-hour baseline continuous video electroencephalogram monitoring (VEM) period, a one-month outpatient dose escalation treatment period, and a second 96-hour continuous VEM treatment period. Upon completion, subjects had the option to enroll in a long-term maintenance period. In addition to the safety evaluation, the efficacy was evaluated with the mean change from baseline in the 28-day seizure rate as an endpoint.
During the long-term SPN-817 maintenance period, the mean reduction in 28-day seizure rate was 71% after 15 months (N=3) and 90% after 32 months (N=2). One subject has been seizure-free for several months. Another subject was discontinued during the maintenance period due to psychiatric reasons that were determined to be unrelated to the study drug. Mild and transient adverse events reported were nausea, difficulty in sleeping, unsteadiness, and nystagmus.
SPN-817 was well tolerated and has an anticonvulsant effect in three subjects with drug-resistant FIAS. 
Authors/Disclosures
Jeanelle Portelli, PhD (Supernus Pharmaceuticals, Inc.)
PRESENTER 		Dr. Portelli has received personal compensation for serving as an employee of Supernus Pharmaceuticals, Inc..
Lovingly Q. Park, PhD (UC Davis Medical Center-neurology) Dr. Park has received personal compensation for serving as an employee of Eli Lilly. Dr. Park has received personal compensation for serving as an employee of Alector. Dr. Park has received personal compensation for serving as an employee of Supernus . Dr. Park has received personal compensation for serving as an employee of Parexel .
Brendan Lujan, PhD Dr. Lujan has received personal compensation for serving as an employee of Supernus Pharmaceuticals, Inc..
Gregory Busse Gregory Busse has received personal compensation for serving as an employee of Supernus Pharmaceuticals.
Jonathan Rubin, MD (Supernus Pharmaceuticals) Dr. Rubin has received personal compensation for serving as an employee of Supernus Pharmaceuticals. Dr. Rubin has stock in Supernus Pharmaceuticals. Dr. Rubin has stock in Atentiv. Dr. Rubin has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file